Mortality and medical utilization in rheumatoid arthritis associated interstitial lung disease: A real-world, large-scale retrospective study comparing Janus kinase inhibitors and tumor necrosis factor inhibitors
- 29 January 2025
- journal article
- research article
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 71, 152636
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- A global federated real-world data and analytics platform for researchJAMIA Open, 2023
- Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic DrugsJAMA Network Open, 2023
- Construction and comprehensive analysis of the biological network related to rheumatoid arthritis‐related interstitial lung diseaseInternational Journal of Rheumatic Diseases, 2022
- Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritisInternational Journal of Rheumatic Diseases, 2022
- Predictors of progression in rheumatoid arthritis‐associated interstitial lung disease: A single‐center retrospective study from ChinaInternational Journal of Rheumatic Diseases, 2022
- A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung diseaseInflammopharmacology, 2022
- Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease: A Population‐Based CohortArthritis Care & Research, 2022
- Rheumatoid Arthritis–Associated Interstitial Lung Disease: Current Update on Prevalence, Risk Factors, and Pharmacologic TreatmentCurrent Treatment Options in Rheumatology, 2020
- The lung in a cohort of rheumatoid arthritis patients—an overview of different types of involvement and treatmentRheumatology, 2019
- Extra-articular manifestations of rheumatoid arthritis: An updateAutoimmunity Reviews, 2011